Abstract
In 2009 the Infectious Diseases Society of America reviewed the guidelines on the treatment of candidemia in non-neutropenic patients. In this document the preferred treatment was either fluconazole or an echinocandin. Amphotericin-B formulations were considered an alternative. However, careful assessment of published data showed similar efficacy between these drugs.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Amphotericin B / adverse effects
-
Amphotericin B / therapeutic use
-
Animals
-
Antifungal Agents / adverse effects
-
Antifungal Agents / therapeutic use*
-
Candidemia / drug therapy*
-
Candidemia / epidemiology
-
Echinocandins / adverse effects
-
Echinocandins / therapeutic use
-
Fluconazole / adverse effects
-
Fluconazole / therapeutic use
-
Fungal Proteins / adverse effects
-
Fungal Proteins / therapeutic use
-
Humans
-
Kidney Diseases / chemically induced
-
Kidney Diseases / epidemiology
-
Neutropenia*
-
Practice Guidelines as Topic / standards*
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Echinocandins
-
Fungal Proteins
-
Amphotericin B
-
Fluconazole
-
echinocandin B